CAJ | 학술논문

目的探讨表皮生长因子受体(EGFR)基因突变状态对于晚期肺腺癌一线化疗的疗效预测意义.方法随访郑州大学附属肿瘤医院2008年10月至2012年3月接受标准一线含铂双联化疗的Ⅳ期肺腺癌患者70例,均经组织学确诊并进行了EGFR基因突变状态检测,其中突变型27例,野生型43例.结果突变组和野生组客观缓解率(ORR)分别为51.85％和32.55％ (P ＜0.01).排除TKI影响后两组无进展生存期(PFS)分别为172 d和138 d(P=0.026).排除后续TKI影响后两组总生存期(OS)分别为426 d和325 d(P =0.104).多因素分析显示,EGFR基因突变状态是PFS的独立影响因素(HR=0.479,区间0.249～0.923,P=0.026).结论 EGFR基因突变是晚期肺腺癌一线含铂双联化疗的疗效预测因素.
목적 탐토표피생장인자수체(EGFR)기인돌변상태대우만기폐선암일선화료적료효예측의의.방법 수방정주대학부속종류의원2008년10월지2012년3월접수표준일선함박쌍련화료적Ⅳ기폐선암환자70례,균경조직학학진병진행료EGFR기인돌변상태검측,기중돌변형27례,야생형43례.결과 돌변조화야생조객관완해솔(ORR)분별위51.85％화32.55％ (P ＜0.01).배제TKI영향후량조무진전생존기(PFS)분별위172 d화138 d(P=0.026).배제후속TKI영향후량조총생존기(OS)분별위426 d화325 d(P =0.104).다인소분석현시,EGFR기인돌변상태시PFS적독립영향인소(HR=0.479,구간0.249～0.923,P=0.026).결론 EGFR기인돌변시만기폐선암일선함박쌍련화료적료효예측인소.
Objective To investigate the prognostic significance of epithelial growth factor receptor(EGFR) gene mutation status in first-line chemotherapy for advanced lung adenocarcinoma.Methods Seventy patients with stage Ⅳ lung adenocarcinoma admitted in tumor hospital affiliated to Zhengzhou university from October 2008 to March 2012,who accepted the standard first-line platinum-based double chemotherapy were followed-up.They were all histologically confirmed and the EGFR gene mutation status was detected,there were 27 cases of gene mutation,43 cases of wild-type mutant.Results The objective response rates of mutation and wild-type mutation were 51.85％ and 32.55％ (P ＜ O.O1).After removing the effect of TKI,progression-free survival (PFS) was 138 days of the wild-type group,172 days of the mutation group (P =0.026),overall survival (OS) was 325 days of wild-type group,426 days of the mutation group(P =0.104).Multivariate analysis showed that EGFR gene mutation status was independent factors for PFS (HR =0.479,range 0.249-0.923,P =0.026).Conclusions EGFR gene mutation is the effect prognostic factor for advanced lung adenocarcinoma first-line platinum-based double chemotherapy.